J Sieper Selected Research

Necrosis

03/2008	Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
06/2006	Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases.
12/2005	Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
10/2005	Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.
06/2003	Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept.
11/2000	Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences.
04/2000	Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4.

41	Ankylosing Spondylitis 03/2008 - 06/2000
7	Necrosis 03/2008 - 04/2000
4	Rheumatoid Arthritis 07/2003 - 04/2000
3	Reactive Arthritis (Reiter Disease) 06/2002 - 02/2000
2	Osteoarthritis 06/2002 - 11/2000
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 05/2007
1	Back Pain (Backache) 09/2006
1	Inflammation 12/2005
1	Anterior Uveitis 08/2005
1	Connective Tissue Diseases (Connective Tissue Disease) 01/2002
1	Mixed Connective Tissue Disease (MCTD) 01/2002
1	Syndrome 01/2002

17	infliximab (Remicade)FDA Link 03/2008 - 06/2000
9	TNFR-Fc fusion protein (etanercept)FDA Link 12/2006 - 06/2003
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2007 - 06/2000
3	Methotrexate (Mexate)FDA LinkGeneric 03/2007 - 04/2000
3	AntigensIBA 06/2002 - 12/2000
2	Sulfasalazine (Azulfidine)FDA LinkGeneric 09/2006 - 04/2002
2	Aggrecans (Aggrecan)IBA 05/2005 - 07/2003
1	celecoxib (Celebrex)FDA Link 03/2008
1	Diclofenac (SR 38)FDA LinkGeneric 03/2008
1	Transforming Growth Factor beta (TGF-beta)IBA 06/2006
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 02/2005
1	leflunomide (Arava)FDA LinkGeneric 01/2005
1	pamidronate (APD)FDA LinkGeneric 08/2003
1	Interferon-gamma (Interferon, gamma)IBA 06/2003
1	HLA-DRB1 antigen (HLA DRB1)IBA 06/2002
1	Prednisolone (Predate)FDA LinkGeneric 01/2002
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2002
1	Carbon MonoxideIBA 01/2002
1	RadiumIBA 04/2001
1	HLA-B27 Antigen (HLA B27 Antigen)IBA 01/2001
1	Interleukin-1 (Interleukin 1)IBA 11/2000
1	Interleukin-1beta (Interleukin 1 beta)IBA 11/2000
1	AntibodiesIBA 11/2000
1	Interleukin-10 (Interleukin 10)IBA 04/2000
1	Interleukin-4 (Interleukin 4)IBA 04/2000
1	Chaperonin 60IBA 02/2000